The aim of this study was to compare the efficacy of EGFR-TKIs(Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors) treatment plus concurrent chemotherapy versus sequential treatment with EGFR-TKIs and chemotherapy in patients with EGFR(Epidermal Growth Factor Receptor)-mutant non-small-cell lung cancer (NSCLC).
Name: pemetrexed
Description: 500mg/m2 ivgtt d1, per three weeksType: DrugPC plus erlotinib PC
Name: cisplatin
Description: 80mg/m2 ivgtt d1, per three weeksType: DrugPC plus erlotinib PC
Name: Erlotinib
Description: 150mg po. every dayType: DrugPC plus erlotinib erlotinib
Description: NCI CTC 4.03
Measure: Adverse Event (AE) Time: 2 monthsAllocation: Randomized
Parallel Assignment
There is one SNP
Inclusion Criteria: - Stage Ⅳ EGFR mutation-positive NSCLC - Initial therapy - ECOG performance status 0-1 Exclusion Criteria: - EGFR mutation-negative - Previous systemic antitumour treatment Inclusion Criteria: - Stage Ⅳ EGFR mutation-positive NSCLC - Initial therapy - ECOG performance status 0-1 Exclusion Criteria: - EGFR mutation-negative - Previous systemic antitumour treatment EGFR Gene Mutation This is an open-label, randomized, parallel-group controlled clinical trial, and the study subjects recruited in this study are NSCLC patients mutant for EGFR gene (19del or L858R). --- L858R ---